Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figs Inc (FIGS) vs Sanofi SA (SNY) Price & Performance

Price performance (Past 24H)

Key statistics

Figs Inc vs Sanofi SA — how do they compare? Figs Inc trades at $14.28 (market cap $2.37B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 44× Figs Inc's market cap, and Sanofi SA pays a 5.55% dividend while Figs Inc pays none. Which is the better fit depends on your goals.

FIGSSNY
Market Cap
$2.37B$104.30B
Sector
Consumer CyclicalHealth
52-Week High
$17.12$52.34
52-Week Low
$6.57$41.33
Enterprise Value
$2.13B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figs Inc

FIGS stock trades at $14.39, up 0.91% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with 28.8% revenue growth, and raised its full-year outlook. Valuation remains elevated with a P/E of 43.24 and P/S of 3.83, while profitability improved with a net income margin of 8.72% in 2025.

The outlook is positive given accelerating revenue growth and margin expansion, but the rich valuation poses a risk if execution falters. Analyst consensus is bullish with a $19.50 price target, though high RSI readings suggest near-term overbought conditions. Key risks include second-half execution challenges and competitive pressures in healthcare apparel.

Sanofi SA

SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.

The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY